Danish pharmaceutical company Novo Nordisk announced that its late-stage clinical trial for ziltivekimab, an experimental anti-inflammatory drug designed to reduce cardiovascular risk, failed to meet its primary objective. The study found that the treatment did not achieve the targeted reduction in major adverse cardiovascular events, including heart attacks, strokes, and cardiovascular-related deaths, compared with a placebo.
The disappointing result represents a significant setback for Novo Nordisk, which acquired the drug through its purchase of Corvidia Therapeutics in 2020 as part of its strategy to expand into cardiovascular disease. Following the announcement, the company's share price fell sharply as investors reassessed the future of its pipeline beyond its blockbuster diabetes and obesity medicines.
Although the trial failed to achieve its main goal, Novo Nordisk said it will continue two ongoing studies evaluating ziltivekimab in patients with heart failure and in people recovering from heart attacks, with results expected in 2027. The company also noted that the outcome is not expected to affect its 2026 financial guidance, although it will record a non-cash impairment charge related to the project.
Health experts say the announcement highlights the challenges of developing new cardiovascular medicines, where promising early results do not always translate into successful late-stage trials. Despite this setback, Novo Nordisk remains one of the world's leading pharmaceutical companies, driven by its successful portfolio of diabetes and obesity therapies.
